Total Funding
30
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
147439
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
Acquired by 
Ironwood Pharmaceuticals
Christian Meyer: Chief Development OfficerPast Role: UniQure, Chief Medical Officer- Alain Bernard: Chief Technology Officer
About the Company
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their
families, not just provide an incremental improvement or benefit over the standard-of-care.
It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
